UCMOK
CNTX icon

United Capital Management of KS’s Context Therapeutics CNTX Stock Holding History

United Capital Management of KS’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,000
Closed -$10.5K – 95
2024
Q4 		$10.5K Buy
+10,000
New +$17.3K ﹤0.01% 86

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

United Capital Management of KS's CNTX Position: Q1 2025 in Review

United Capital Management of KS sold out of Context Therapeutics (CNTX) in Q1 2025, closing a stake of 10,000 shares — an estimated $10.5K sold.

United Capital Management of KS first reported a position in CNTX in Q4 2024 and held it in 1 quarter. The position peaked at $10.5K in Q4 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q1 2025.

  • United Capital Management of KS reported no remaining Context Therapeutics position as of Q1 2025 after selling out during the quarter.
  • United Capital Management of KS sold 10,000 Context Therapeutics shares in Q1 2025, an estimated $10.5K.
  • United Capital Management of KS first reported a position in Context Therapeutics in Q4 2024 and held it in 1 quarter.
  • United Capital Management of KS's Context Therapeutics position peaked at $10.5K in Q4 2024.
  • 42 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2025.

Based on United Capital Management of KS's 13F filing for Q1 2025, filed 13 May 2025.